Key Stats for Boston Scientific Stock
- Current Price: $69.17
- Target Price (Mid): $117.15
- Street Target: $101.84
- Potential Total Return: +69.4%
- Annualized IRR: 11.70% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Few medtech stocks have had a rougher six months than Boston Scientific (BSX).
After reaching a 52-week high of $109.50, shares fell to a low of $67.56, a maximum drawdown of 36.98% as of March 24, 2026.
The selling started on February 4, when the company disclosed slower-than-expected U.S. electrophysiology market growth and issued 2026 organic growth guidance of 10% to 11%, well below what the Street had priced in, sending shares down 17.6% in a single session.
A securities class action lawsuit was subsequently filed alleging that executives overstated the sustainability of electrophysiology growth. Those are unproven allegations, and the company has not conceded any wrongdoing.
Then, on March 28, the question the market had been holding its breath over was answered.
Boston Scientific announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints, with results presented as a late-breaking trial at the American College of Cardiology’s 75th Annual Scientific Session and simultaneously published in the New England Journal of Medicine. Dr. Ken Stein, Boston Scientific’s Chief Medical Officer, described both trials at the ACC conference as “having the potential to be practice transforming.”
The study evaluated the WATCHMAN FLX Left Atrial Appendage Closure device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation.
WATCHMAN FLX is Boston Scientific’s permanently implanted device that seals off the left atrial appendage, the small pouch in the heart where most AF-related blood clots form, so patients can avoid lifelong blood thinner therapy.
The clinical case rests on a stubborn real-world gap: 40% of patients with AF who are prescribed blood thinners for stroke risk reduction are not taking their medications consistently, significantly increasing their risk of stroke.
Dr. Brad Sutton, Chief Medical Officer of AF Solutions, put it plainly: “The CHAMPION-AF data add to Boston Scientific’s robust body of clinical evidence supporting the WATCHMAN device as a one-time implant that helps provide stroke risk protection over a patient’s lifetime.”
See historical and forward estimates for Boston Scientific stock (It’s free!) >>>
Is Boston Scientific Undervalued Today?
At $69.17, BSX trades at 16.69x NTM EV/EBITDA and 19.95x NTM P/E, down sharply from 26.48x and 33.08x, respectively, at the end of 2024.
The underlying business is not the problem.
Revenue grew 19.9% in 2025 to $20.07 billion, with the Cardiovascular segment generating $13.27 billion of that total. Free cash flow reached $3.66 billion, up 38.3% year over year.
The market is discounting BSX because it has lost confidence in the sustainability of that growth, particularly in electrophysiology.
CHAMPION-AF speaks directly to that concern.
Before the trial, WATCHMAN was primarily indicated for patients with high bleeding risk or intolerance to anticoagulants, a global pool of roughly 5 million patients. Dr. Sutton told analysts at the ACC call that the data “paves the way to quadruple that number by 2030 and beyond,” targeting 20 million indicated patients worldwide.
The headline numbers: WATCHMAN FLX achieved statistical non-inferiority to NOACs for the composite of stroke, cardiovascular death, or systemic embolism (5.7% versus 4.8%), and, including procedural bleeding in a secondary analysis, demonstrated a 34% relative reduction in bleeding risk (12.8% versus 19.0%).
The trade-off physicians and investors both need to weigh is an annualized 0.33% difference in ischemic stroke rates against a roughly 2.6% annual reduction in clinically meaningful bleeding.
Dr. Marty Leon, Study Co-Chair and Chief Innovation Officer at Columbia University Medical Center, described that as the basis for “meaningful conversations with patients,” particularly given that real-world NOAC adherence runs around 60%, far below the near-90% rate sustained in the trial.
Some independent cardiologists called the borderline-significant increase in ischemic strokes in the WATCHMAN arm a “pretty concerning endpoint,” and the adoption path runs through multiple hurdles: an FDA label submission, updated clinical guidelines, and a new CMS National Coverage Decision (NCD) to unlock broader reimbursement.
Dr. Stein was direct on the timeline: “We wouldn’t be submitting this to the FDA if we didn’t believe the data support getting the label update.” Each step takes time, and the full commercial unlock is not a 2026 story.
On CLOSURE-AF, published concurrently and cited by some skeptics, Stein noted its 92% screen failure rate, procedural complication rates five times higher than CHAMPION-AF, and 46% of patients enrolled at just three centers.
He is planning a meta-analysis combining CLOSURE, CHAMPION, PRAGUE-17, and OPTION to give investors and clinicians a cleaner read on the ischemic stroke question across all four randomized trials.
Boston Scientific also presented HI-PEITHO at the same ACC session, a 544-patient randomized trial showing its EKOS system (which combines a catheter with ultrasound energy to dissolve blood clots) significantly outperformed anticoagulation alone for intermediate-risk pulmonary embolism patients (p=0.005), with no difference in major bleeding and zero intracranial hemorrhages.
See how Boston Scientific performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
Key Stats:
- Current Price: $69.17
- Target Price (Mid): $117.15
- Potential Total Return: +69.4%
- Annualized IRR: 11.70% / year
See analysts’ growth forecasts and price targets for Boston Scientific stock (It’s free!) >>>
The TIKR mid-case model projects an 8.3% revenue CAGR through December 31, 2030, reaching a target price of $117.15. The margin driver is operating leverage, with net income margins projected to expand from 22.8% in 2025 toward 24.8% by the end of the forecast period. The primary risk is regulatory timing: if FDA label expansion and the CMS NCD take longer than management expects, WATCHMAN adoption could stall at the existing patient base and compress growth toward the low-case 7.5% CAGR, producing a $118.79 target at a 6.4% IRR. Even the downside produces positive returns from current levels because the stock has already absorbed significant pessimism. The high case prices in successful first-line positioning and expanded PE market penetration, producing a $187.48 target at a 12.0% IRR.
Conclusion: Watch the WATCHMAN procedure volume at the next earnings report on April 22, 2026. Management guided 20% WATCHMAN market growth for 2026 before CHAMPION-AF results were public. Any volume acceleration above that threshold in Q1 would signal that physicians are already moving ahead of formal label and reimbursement changes, validating the bull case. A figure below 15% would suggest the market is waiting for the regulatory pathway to clear first.
BSX is a high-quality medtech franchise repriced from a growth stock to a show-me story. The CHAMPION-AF data gave management the clinical foundation to start rebuilding that case. The question is whether the regulatory timeline matches investor patience.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Boston Scientific?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Boston Scientific, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Boston Scientific alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Boston Scientific on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
